Fluidigm Corporation (NASDAQ:FLDM) Sets New 12-Month Low at $2.71

Fluidigm Corporation (NASDAQ:FLDM) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $2.71 and last traded at $2.71, with a volume of 291,492 shares traded. The stock had previously closed at $3.15.

A number of research analysts recently issued reports on FLDM shares. ValuEngine downgraded Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research downgraded Fluidigm Corporation from a “hold” rating to a “sell” rating in a research note on Friday, May 12th.

The company’s market capitalization is $107.07 million. The firm’s 50-day moving average is $3.70 and its 200 day moving average is $4.85.

Fluidigm Corporation (NASDAQ:FLDM) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.02. The business had revenue of $23.90 million for the quarter, compared to the consensus estimate of $23.50 million. Fluidigm Corporation had a negative return on equity of 121.04% and a negative net margin of 74.05%. The company’s revenue for the quarter was down 15.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.63) earnings per share. Equities analysts anticipate that Fluidigm Corporation will post ($2.19) earnings per share for the current fiscal year.

In other news, insider Levin Capital Strategies, L.P. acquired 4,003,129 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $3.30 per share, for a total transaction of $13,210,325.70. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Evan/ Fa Jones sold 10,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $4.54, for a total transaction of $49,486.00. The disclosure for this sale can be found here. Insiders have bought 4,106,038 shares of company stock valued at $13,496,083 over the last quarter. Company insiders own 4.70% of the company’s stock.

A number of large investors have recently made changes to their positions in FLDM. Wellington Management Group LLP raised its stake in shares of Fluidigm Corporation by 2.4% in the first quarter. Wellington Management Group LLP now owns 630,277 shares of the medical research company’s stock worth $3,587,000 after buying an additional 14,814 shares in the last quarter. Neuberger Berman Group LLC raised its stake in shares of Fluidigm Corporation by 58.1% in the first quarter. Neuberger Berman Group LLC now owns 1,924,408 shares of the medical research company’s stock worth $10,950,000 after buying an additional 707,410 shares in the last quarter. American International Group Inc. raised its stake in shares of Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock worth $102,000 after buying an additional 1,187 shares in the last quarter. Levin Capital Strategies L.P. raised its stake in shares of Fluidigm Corporation by 0.6% in the first quarter. Levin Capital Strategies L.P. now owns 5,789,282 shares of the medical research company’s stock worth $32,941,000 after buying an additional 33,529 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Fluidigm Corporation by 20.5% in the first quarter. Bank of New York Mellon Corp now owns 206,578 shares of the medical research company’s stock worth $1,175,000 after buying an additional 35,176 shares during the last quarter. Institutional investors and hedge funds own 91.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/19/fluidigm-corporation-nasdaqfldm-hits-new-52-week-low-at-2-71-updated.html.

Fluidigm Corporation Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

What are top analysts saying about Fluidigm Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fluidigm Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit